Updates are available Correction dated 2024-07-18

Article History

Received: 6 February 2024

Accepted: 25 March 2024

First Online: 4 May 2024

Change Date: 18 July 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1245/s10434-024-15886-6

Disclosure

: Dr. Jonathan Zager–global principal investigator in the FOCUS phase 3 study and serves on Delcath Systems Medical Advisory Board. Education and Training grant through Delcath. Dr. Marlana Orloff–Advisory Board: Delcath, Replimune. Consultant: Immunocore. Steering Committee: Ideaya. Speaker: Immunocore. Dr. David Eschelman–Received <$5K consulting fees from Delcath. Dr. Evan Glazer–My institution was a site for the clinical trial. I received no direct payment. Delcath paid for the clinical trial to my institution. Dr. J. Howard–I was paid as a consultant to Delcath as a proctor for this trial to ensure new institutions adhered to protocol. Prof. Erika Richtig–Medical University of Graz received payments for conducting the Phase 3 study. Dr. Sebastian Ochsenreither–Advice: Immunocore, Delcath, Janssen. Speakers’ bureau: Immunocore. Dr. Georgia Beasley–Clinical trial funding paid to institution from Replimune, checkmate pharmaceuticals, Philogen, Delcath. Advisory board BMS 10.2023. Dr. Anja Gesierich–University Hospital Würzburg received payments for conducting the Phase 3 study. Professor Reinhard Dummer–intermittent, project focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dhome (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer, Simcere and touchIME outside the submitted work. Dr. Ana Arance–Consulting or advisory role: Pierre- Fabre, Novartis, Roche, BMS, MSD, Biontech. Speakers’ Bureau: Pierre- Fabre, Novartis, Roche, BMS, MSD. Travel, Accommodations, Expenses: BMS, MSD. Mr. Stephen Fenwick–Liverpool University Hospitals NHS Trust received support for conducting this Phase 3 study from the trial sponsor. Dr. Joseph Sacco–I have been a paid member of advisory boards for Delcath, Replimune and Immunocore. I have received grant funding from Astra Zeneca and BMS (paid to institution). I have had travel and conference attendance paid for by MSD, BMS and Replimune. Dr. Matthew Wheater–Institutional (University Hospital Southampton) funding for conducting a commercial trial. Personal funding for participation in advisory board for Delcath.